Core Insights - The company reported a revenue of 236 million yuan in the first half of 2025, a year-on-year decrease of 4.61%, and a net profit attributable to shareholders of 69.696 million yuan, down 14.32% year-on-year [1] - The company focuses on the research and innovation of ultrasound medical imaging equipment, aiming to become a global leader in high-end ultrasound medical imaging devices and services [1] - The company has integrated AI technology into its SonoAI platform, enhancing its SonoFamily product line with capabilities such as lesion intelligent recognition and image self-optimization [1] Product Development - The company has expanded its cardiac ultrasound solutions with high-resolution imaging, precise hemodynamic analysis, and intelligent cardiac function assessment, addressing diverse needs in the cardiac ultrasound field [2] - The company has made significant progress with its "breast AI ultrasound robot," which features an integrated design for large-scale scanning and data tracking management, supporting a full-cycle service model from screening to treatment [2] Market Expansion - The company has launched the SonoVet series for veterinary ultrasound, which combines AI and 5G remote diagnostic technology, catering to various environments such as farms and pet hospitals [3] - A recent policy from the National Medical Products Administration supports the innovation of high-end medical devices, which is expected to provide significant market opportunities for companies focusing on AI and high-end medical imaging [3] - The company aims to enhance its competitiveness in the ultrasound medical imaging field through innovation-driven strategies and international expansion [3]